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DNA methylation at CpG motifs provides an epigenetic route to regulate gene expression.
In general, an inverse correlation between DNA hypermethylation at CpG motifs and gene
expression is observed. Epstein Barr-virus (EBV) infects people and the EBV genome
resides in the nucleus where either its replication cycle initiates or it enters a long-term
latency state where the viral genome becomes hypermethylated at CpG motifs. Viral gene
expression shows a largely inverse correlation with DNA hypermethylation. DNA
methylation occurs through the action of DNA methyl transferase enzymes: writer
DNA methyl transferases add methyl groups to specific regions of unmethylated DNA;
maintenance DNA methyl transferases reproduce the pattern of DNA methylation during
genome replication. The impact of DNAmethylation is achieved through the association of
various proteins specifically with methylated DNA and their influence on gene regulation.
DNA methylation can be changed through altering DNA methyl transferase activity or
through the action of enzymes that further modify methylated CpG motifs. Azacytidine
prodrugs that are incorporated into CpG motifs during DNA replication are recognized by
DNA methyl transferases and block their function resulting in hypomethylation of DNA.
EBV-associated cancers have hypermethylated viral genomes and many carcinomas also
have highly hypermethylated cellular genomes. Decitabine, a member of the azacytidine
prodrug family, reactivates viral gene expression and promotes the recognition of
lymphoma cells by virus-specific cytotoxic T-cells. For EBV-associated cancers, the
impact of decitabine on the cellular genome and the prospect of combining decitabine
with other therapeutic approaches is currently unknown but exciting.
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DNA methylation at the 5-position of the cytosine ring of CpG motifs in DNA provides an
epigenetic route to regulate gene expression (Klose and Bird, 2006). Extensive DNA methylation is
generally associated with mammalian genes that are not expressed (Suzuki and Bird, 2008), with
some cell-type specific genes showing a consistent pattern of DNAmethylation found in key regions
of the genome (Schmidl et al., 2009).gy | www.frontiersin.org May 2021 | Volume 11 | Article 6950931
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maintained by the interplay of several activities within the cell. 1.
De novo DNA methyl transferases enzymes (also termed
‘writers’) are responsible for the initial addition of methyl
groups to previously unmethylated CpG motifs . 2.
Maintenance DNA methyl transferases enzymes are
responsible for maintaining the DNA methylation pattern in
daughter cells by adding methyl groups to the newly replicated
strand of the hemi-methylated CpG motifs that are synthesized
during genome replication (Klose and Bird, 2006). 3. A set of
‘eraser’ enzymes work in effective opposition to the DNA methyl
transferases, by modifying the methylation mark (Tsiouplis et al.,
2020). 4. A set of proteins termed ‘readers’ specifically recognize
and bind to methylated CpG motifs and recruit other proteins to
that region of the genome. Together, these enzymes act to mark
the expression of linked genes (Mahmood and Rabbani, 2019).
The mechanism by which the methylated state of the DNA is
able to alter gene expression mediate through the action of
methyl-DNA binding proteins that recruit chromatin modifiers
(Du et al., 2015).
Epstein-Barr virus (EBV) is a common virus that infects
people in a generally asymptomatic manner. The virus resides
for life within the pool of B-lymphocytes (Thorley-Lawson and
Babcock, 1999). For most people, EBV infection is asymptomatic,
but it can cause infectious mononucleosis (IM, glandular fever)
and a range of cancers both carcinomas (Gastric, Nasopharyngeal)
and lymphomas (Burkitt’s lymphoma, Hodgkin’s lymphoma, NK/
T-cell lymphoma, diffuse large B-cell lymphoma and post-
transplant-like lymphoma) (Vetsika and Callan, 2004; Shannon-
Lowe and Rickinson, 2019). EBV lytic replication and production
of infectious virus is rare in cancer cells; by this stage the virus has
entered into a latent state. The viral genome is maintained in the
cancer cells by replicating once per cell cycle in time the host
genome, but few viral genes are expressed. The EBV genome
consists of double strand DNA and following infection it resides as
a circular form in the nucleus of infected cells (Tsurumi et al.,
2005; Hammerschmidt and Sugden, 2013). As with the cellular
genome, the EBV genome is subject to DNA methylation at CpG
motifs and, analogous to the cellular genome, DNAmethylation of
the viral genome is strongly linked to gene expression (Minarovits,
2006). The DNAmethylation pattern of the EBV genome changes
during its life-cycle, being largely unmethylated in the infectious
virion, then gaining methylation following the infection of cells
(Bergbauer et al., 2010). By the time that EBV-associated
carcinomas and lymphomas develop, the viral genome is heavily
methylated at CpG motifs and few of the approximately 90 viral
genes are expressed (Shannon-Lowe and Rickinson, 2019).
The cellular genomes of cancers can also be impacted by DNA
methylation. Importantly, some EBV-associated cancers exhibit
very high levels of DNA methylation of the cellular genome that
correlates with reduced expression of specific tumour suppressor
genes (Bass et al., 2014; Stanland and Luftig, 2020).
Deliberately attempting to reduce the DNA methylation in
EBV-associated cancer with the aim of activating the expression
of cellular and viral genes has the potential to achieve two
potentially therapeutic events. First, it may result inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2reactivation of the expression of viral genes that expose the
cells to attack by the immune system. Secondly, it may result in
the expression important cellular genes that cause the cancer
cells to stop proliferating or to die through apoptosis.
Deliberately attempting to alter DNA methylation therefore
presents an attractive research direction which may lead to
new therapeutic approaches to treat EBV-associated cancer in
the future.
Enzymes That Regulate DNA Methylation
The process of establishing this epigenetic change to gene
expression is undertaken through the deposition of DNA
methylation onto the cytosine residues of CpG motifs in
genomes by de novo DNA methyltransferase (DNMT)
enzymes that add a methyl group to the cytosine of specific
CpG motifs (Klose and Bird, 2006). The individual roles of de
novo DNA methyl transferases DNMT3A and DNMT3B for
methylating regulatory regions of developmental genes and the
X-chromosome respectively, have been established and they are
also candidates to accomplish de novo DNA methylation in
somatic cells (Law and Jacobsen, 2010). Once established, the
DNA methylation pattern is copied during each cycle of DNA
replication by the action of the maintenance DNA methyl
transferase, DNMT1 (Law and Jacobsen, 2010); thereby
maintaining the set pattern of DNA methylation in daughter
cells. As methylated DNA replicates, hemi-methylated CpG
motifs consisting of the methylated template DNA strand and
the newly replicated and so unmethylated strand are produced.
DNMT1 recognizes the hemi-methylated CpG motif and adds a
methyl group to the cytosine (Figure 1).
The effective removal of CpG DNA methylation on the host
genome occurs through one of two routes. If the maintenance
DNMT enzyme is compromised during DNA replication then
hemi-methylated CpG motifs will be present after one round of
replication with the potential for fully unmethylated CpG motifs
after a second round of replication. The second route is achieved
through the actions of a set of proteins (Ten-Eleven-
Translocation (TET) family) that further modify the methyl-
group on CpG motifs. (Tsiouplis et al., 2020).
DNA Methylation of the Host and Viral
Genomes in EBV-Associated Cancer
Global methylome analysis of over 30 different cancer types by
The Cancer Genome Atlas Network (TCGA) revealed that the
highest level of hypermethylation of cellular DNA occurred in
Epstein-Barr virus associated Gastric Carcinoma (Bass et al.,
2014). Affected genes include a set of tumour suppressor genes
(Okada et al., 2013; He et al., 2015; Nishikawa et al., 2018).
Hypermethylation of cellular DNA is also seen in Epstein-Barr
virus associated Burkitt’s lymphoma and Nasopharyngeal
carcinoma, but to a lesser degree (Stanland and Luftig, 2020).
In EBV-associated carcinomas and lymphomas, the EBV
genome is also subject to widespread DNA methylation and
highly restricted patterns of viral gene expression (Minarovits,
2006). Immediately following infection of cells, transient low-
level expression of many of the 90-viral genes occurs from theMay 2021 | Volume 11 | Article 695093
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rapidly subject to DNA methylation at CpG motifs and settles
into one of several highly restricted sets of viral latency gene
expression (Tierney et al., 2000; Bergbauer et al., 2010). Three
major patterns are common in cancer (latency I, II (also termed
IIa) and III), but other patterns of viral gene expression exist
including Wp-restricted (Kelly et al., 2009) and IIb latency (Price
and Luftig, 2015). Around 90% of the EBV genes are not
expressed in any lymphomas and carcinomas, and for the
majority of the EBV-associated cancers, the promoters driving
expression of the genes generating the most immunogenic T-cell
responses (EBNA 2 and 3 family) are not expressed (Minarovits,
2006). In addition, the lytic replication cycle genes (especially
BZLF1, BRLF1, BMRF1 and BMLF1) which are highly
immunogenic are also silent (Taylor et al., 2015). So, the EBV
genome itself provides a wealth of immunogenic genes that are
often silenced by DNA hypermethylation.
Clues about how the hypermethylation of cellular and viral
DNA occurs in EBV-associated cancer comes from cell culture
experiments where it was demonstrated that de novomethylation
of cellular DNA occurs within days of EBV infection (Queen
et al., 2013). Two EBV genes have been implicated: LMP1 and
LMP2A. LMP1 activates the expression of both de novo and
maintenance DNA methyl transferases (Tsai et al., 2006; Peng
et al., 2016) and so could both aid the initiation and ensure the
maintenance of the DNA methylation changes. LMP1 is
expressed in some but not all EBV-associated cancer, however,
it has been shown to be expressed transiently after EBV infection
of gastric epithelial cells (Matsusaka et al., 2017) in addition to
during the immortalization of B-lymphocytes by EBV. It is
therefore conceivable that LMP1 might play a transient early
role in reprogramming DNA methylation in EBV-associated
cancers. In addition, LMP2A which is expressed in some but
not all, EBV-associated cancers, drives the upregulation of theFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3maintenance DNA methyl transferase (Hino et al., 2009) and the
down regulation of TET gene expression (Namba-Fukuyo et al.,
2016). These changes indicate that LMP2A is also a candidate to
contribute to global increases in DNA methylation in EBV-
associated cancers.
A further piece in this puzzle is the enduring impact of EBV
on hypermethylation of the cellular genome even after the viral
genome has been lost from the cells (Birdwell et al., 2014). So,
clues about the mechanisms by which the hypermethylation of
the cellular and viral genomes occurs have been identified and it
is possible that LMP1 and LMP2A play transient roles in
reprogramming DNA methylation early after entry into cells.
The correlation of EBV-associated gastric cancer with DNA
hypermethylation of the cellular genome, the potential
contribution of EBV genes to changing the expression of
components of the DNA methylation machinery and the
relevance of the genes that are potentially silenced by
hypermethylation in EBV-associated gastric cancer all support
the hypothesis that actively demethylating the genome of EBV-
associated cancer cells may be beneficial.
Impact of Changing the DNA Methylation
in EBV-Infected Cells
Attempts to alter the DNA methylation within EBV-infected
cells focus on the maintenance DNA methyltransferase. The
impact of totally inhibiting the action of the maintenance DNA
methyl transferase would be the hypomethylation of the cellular
and viral genomes within 1-2 rounds of cell replication (Mani
and Herceg, 2010). The reduction in the DNA methylation
landscape resulting from this in EBV infected cells is predicted
to have impacts on the expression of both viral and cellular genes
with the potential for immunogenic viral genes rendering the
cancer cells susceptible to attack by the immune system and of
tumour suppressor genes reducing growth and survival of theFIGURE 1 | Impact of decitabine and 5’ azacytidine on the maintenance methylation of DNA during genome replication. The presence of an isolated C and two
CpG motifs in genome are shown prior to replication. The methylation group on each methyl cytosine of the central CpG motif is shown (blue triangle). Following one
round of semi-conservative DNA replication hemi-methylated CpG motifs occur. These are recognized by DNMT1 and a methyl group added to the unmethylated
cytosine. Thus the end product has the same methylation state as the genome prior to replication. In the presence of decitabine or 5’aza-cytidine, these modified
bases are incorporated into the newly synthesized strand (shown in red). The hemi-methylated CpG motifs are recognized by DNMT1, and are covalently bound to
the modified cytosine bases. The genome remains in a hemi-methylated state.May 2021 | Volume 11 | Article 695093
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approach and it may also drive unfavorable changes in cellular
gene expression.
Cytidine analogues that irreversibly inhibit the maintenance
DNA methyl transferases and so promote hypomethylation of
DNA were identified over 50-years ago (Sorm et al., 1964; Sorm and
Vesely, 1968) - 5’Azacytidine (4-Amino-1-(b-D-ribofuranosyl)-1,3,5-
triazin-2(1H)-one; azacytidine, 5-aza-CR; Vidaza®) and its
deoxyribose version, Decitabine (2′-Deoxy-5-azacytidine, 4-Amino-
1-(2-deoxy-b-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one, 5-aza-CdR;
Dacogen®). Both cytidine analogues are processed within cells to the
triphosphate derivatives and can be incorporated into newly
synthesized DNA during the S-phase of the cell replication cycle
(Figure 1) (Mani and Herceg, 2010). Once embedded within the
genome thosemodified bases formhemi-methylated CpGmotifs that
are recognized by the maintenance DNAmethyl transferase and they
irreversibly trap and inhibit the DNMT1, leading to rapid
hypomethylation of CpG motifs throughout the genome (Figure 1)
(Howell et al., 2010; Mani and Herceg, 2010).
Preclinical studies showed that both 5’azacytidine and
decitabine are highly active cytotoxic agents against many
types of cancer cells (Howell et al., 2010). Furthermore, clinical
studies showed that both 5’azacytidine and decitabine are
beneficial for people with some forms of haematological cancer
(Silverman et al., 2002; Kantarjian et al., 2006; Fenaux et al., 2009;
Benton et al., 2014; Mayer et al., 2014). A 5’Azacytidine smallFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4scale trial in patients with EBV-associated cancers revealed that
demethylation of the viral genome was successfully achieved
(Chan et al., 2004).
Impact of Decitabine as a Demethylation
Agent of the EBV Genome in
EBV-Infected Cells
An exciting new development in the fight to reprogram the
epigenetics of EBV-infected cells to make them sensitized to
immunotherapy was reported recently (Dalton et al., 2020). This
builds on previous successes of infusing virus-antigen-specific
autologous or allogeneic CTLs to treat EBV cancers (Heslop
et al., 2010; Bollard et al., 2014; Bollard and Barrett, 2014; Chia
et al., 2014; Kazi et al., 2019; Prockop et al., 2020). Dalton
hypothesized that if they could reactivate expression of viral
antigens using sub-cytopathic doses of drugs, the cancer cells
may become primed for immune attack. In a search to re-
purpose drugs that could promote the expression of antigenic
viral genes in the aggressive B-lymphomas that express the most
restricted pattern of EBV gene expression (latency I), they
identified decitabine as a strong candidate to reprogram the
expression of immunogenic viral latency genes. Decitabine
induced the expression of the two key viral promoters, with
the resulting proteins identified in 27-58% of cells in a cell culture
model system (Figure 2) (Dalton et al., 2020). Excitingly, the
reprograming of viral gene expression was reproduced in a moreFIGURE 2 | Reversing epigenetic silencing of the viral genome allows recognition by T-cells. EBV-associated cancer cells are shown in blue. In the top panel the
viral genome (red oval) is hyper methylated at CpG motifs and largely silent. MHC is shown at the cell surface (blue shape). In the bottom panel, following decitabine
treatment, the genome is de-methylated (red dashed-line oval), reactivated and expresses immunogenic viral proteins (red) that are displayed with MHC as peptides
at the surface of the cell. This allows the EBV-specific T-cells (yellow) to recognize the cancer cells.May 2021 | Volume 11 | Article 695093
Sinclair Virus DNA Methylation Therapy?physiologically challenging mouse xenograft tumour model and
the change in gene expression was shown to have a durable
impact. Importantly, EBV-specific CTLs were able to recognise
and kill the decitabine-treated tumour cells in vitro and critically
they were shown to infiltrate the xenograft tumours in vivo
(Figure 1) (Dalton et al., 2020), providing proof-of-principle.DISCUSSION
The pressing question is whether decitabine treatment could
provide a relevant clinical approach to treat EBV-associated
lymphomas and carcinomas? Decitabine has a proven potential
to drive hypomethylation of the viral genome and to prime EBV-
associated lymphoma cells to re-express immunogenic viral genes
(Dalton et al., 2020). This provides the first part of a potential
therapeutic strategy. In combinationwith the action of the patient’s
existing immune response, this may be sufficient to boost an
immune attack, or this could be supplemented by infusion of
EBV-specific CTLs or T-cells expressing EBV-specific chimeric
antigen receptors (CAR-T therapy) (Chicaybam et al., 2019;
Dragon et al., 2020; Prockop et al., 2020; Heslop et al., 2021).
However, a potential limitation to this approach is that the EBV
genome was not reactivated in every lymphoma cell following
decitabine treatment (Dalton et al., 2020), and so not all tumor
cells would be rendered susceptible to immune attack. Whether
reactivation could be stimulated to generate a homogeneousFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5response remains an open question. Interestingly, the sub-
cytopathic dose of decitabine used appeared sufficient to stop the
lymphoma growing (Dalton et al., 2020). Alterations to host gene
expression might also occur as a result of decitabine and may
negatively impact on the growth or survival of tumor cells. The
recent discovery that LMP1directs the expression of a set of tumor-
associated antigens in a B-lymphoma that are recognized by T-cells
(Choi et al., 2021) supports this avenue, although it is not knownyet
whether the changes in gene expression involves a change in DNA
methylation. Changes in expression of cellular genes may be
especially relevant for EBV-associated carcinomas, where a high
proportion of the cellular genome is methylated. In addition, in
non-EBV infected cells it has recently been shown that decitabine
can act in combination with chemotherapy to improve its efficacy
(Wu et al., 2019). This suggests another avenue of research for
combined EBV-associated cancer treatments.
The recent advances that allow for the reversal of DNA
methylation and epigenetic silencing of viral gene expression and
those that develop specific viral immunotherapies provide
promising avenues of research for EBV-associated cancers in
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